Meningeal inflammation is a key and persistent driver of multiple sclerosis (MS) pathogenesis both early in the disease and at later progressive stages. 1 Immune cell infiltration, either dispersed or concentrated into lymphoid-like structures, have been pathologically documented in the subarachnoid space in association with underlying cortical tissue damage. Such tissue damage may include demyelination, neuronal injury, and microglia activation, which is sometimes more spatially pronounced in the superficial cortical layers. 2 The intrathecal clonal expansion of plasma cells contributes to the production of cerebrospinal fluid (CSF)-restricted oligoclonal bands, that is, the most frequent detected CSF biomarker in MS (up to 90% of patients) and that was recently reincluded in the MS diagnostic criteria. 3 The secretion of other soluble molecules in the CSF, including proinflammatory and neurotoxic cytokines (including TNF, IFNγ, IL2) and factors relevant for B-lymphocytes activity, is thought to directly lead to cortical pathology, neurodegeneration, and, hence, relentless disability accrual. 4 Whereas histopathological assessment lacks information about time course, CSF profiling of meningeal inflammation might miss critical spatial information. For this reason, we sustain the position that the potential of monitoring the spatiotemporal distribution and evolution of meningeal inflammation with an in vivo imaging technique, as is currently done for accrual of demyelinating lesions and brain atrophy, is extremely valuable and should be a part of the clinical routine. This becomes even more relevant for monitoring, less invasively, the effect of newly introduced (e.g. ocrelizumab) or future treatments targeting critical components of meningeal inflammation, such as B cells.
Despite this premise and the disease-relevant association between meningeal inflammation and cortical damage in MS, two major drawbacks have reduced, so far, the incorporation of techniques for imaging meningeal inflammation into clinical practice: (1) relatively little research effort has been invested toward the investigation of meningeal inflammation in vivo with magnetic resonance imaging (MRI) or other imaging techniques and (2) techniques for in vivo imaging of cortical demyelinated lesions are suboptimal compared to histological studies.
To date, only one imaging biomarker has been proposed to potentially show correlation with leptomeningeal inflammation in MS. In 2015, using delayed postcontrast T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) MRI, we reported the visualization in vivo of areas of leptomeningeal inflammation that lead to breakdown of the blood-meningeal barrier (seen as locally restricted leakage of gadolinium in the subarachnoid space, or leptomeningeal enhancement (LME)) and validated this finding pathologically. 5 It is well known that delayed postcontrast T2-FLAIR has greater sensitivity than routine postcontrast T1-weighted MRI to uncover gadolinium enhancement in the subarachnoid space. The practical advantage of our approach for clinical application is that T2-FLAIR is one of the most common MRI sequences used for routine detection of MS lesions, and moving the T2-FLAIR sequence to the end of an MRI protocol (after gadolinium injection) would not increase the total duration of the exam.
As of this writing, the medical literature contains data on LME in ~700 MS patients, [5] [6] [7] [8] [9] from which the prevalence of LME can been estimated to be ~30% at 3T 5, 6, 8 and potentially as high as 90% at 7T MRI (based on data from a single study of 29 cases). 7 Overall, the prevalence of LME appears to be higher for progressive clinical phenotypes. 5 In both crosssectional and longitudinal evaluations, associations with clinical disability and cortical thinning have been consistently shown, sustaining the disease-relevance of this radiological finding. [5] [6] [7] [8] 10 Differently from the more well-known parenchymal enhancement that is found at the onset of a demyelinating 
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MP Wattjes and J Killestein lesion, LME is a long-lasting radiological finding (at least over several years), suggesting, perhaps, impaired recovery of the blood-meningeal barrier in a persistently inflammatory niche.
Some caveats need to be considered as well. In existing autopsy cases that allow radiological-pathological correlation, LME is associated with lymphocytes and monocytes/macrophages gathered around leptomeningeal venules and spatially associated with subpial cortical demyelination; 5 however, the spatial link between LME and cortical demyelinated lesions has not been conclusively shown in vivo. In addition, by definition, LME on postcontrast T2-FLAIR is not sensitive to inflamed meningeal areas with a partially intact blood-meningeal barrier or in which gadolinium does not concentrate within the subarachnoid space. Finally, LME does not appear to respond to treatments routinely used for MS, though there are preliminary indications that corticosteroids might induce transient modulation of the finding.
These caveats are not unusual when new findings are reported through the application of new techniques;
there are numerous open research questions that need to be properly addressed. Thus, the key phrase in the title of this article is "should become": with proper investment of research resources, imaging of meningeal inflammation will eventually be a critical part of the clinical routine in MS imaging.
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